

Heather A Parsons

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1522732/publications.pdf>

Version: 2024-02-01

28
papers

2,104
citations

535685

17
h-index

591227

27
g-index

30
all docs

30
docs citations

30
times ranked

4620
citing authors

#	ARTICLE	IF	CITATIONS
1	Massively parallel enrichment of low-frequency alleles enables duplex sequencing at low depth. <i>Nature Biomedical Engineering</i> , 2022, 6, 257-266.	11.6	32
2	Late Recurrence Following Early Breast Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 1400-1406.	0.8	9
3	Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 2408-2419.	0.8	42
4	Aiming for the Cure in ERBB2-Positive Metastatic Breast Cancer—Should We Go “All In?” Reply. <i>JAMA Oncology</i> , 2022, 8, 1221.	3.4	8
5	Circulating tumor DNA in advanced solid tumors: Clinical relevance and future directions. <i>Ca-A Cancer Journal for Clinicians</i> , 2021, 71, 176-190.	157.7	101
6	Adjuvant Capecitabine in Triple-Negative Breast Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 36.	3.8	17
7	Phase II Single-Arm Study to Assess Trastuzumab and Vinorelbine in Advanced Breast Cancer Patients With HER2-Negative Tumors and HER2-Positive Circulating Tumor Cells. <i>JCO Precision Oncology</i> , 2021, 5, 896-903.	1.5	6
8	Modeling clonal structure over narrow time frames via circulating tumor DNA in metastatic breast cancer. <i>Genome Medicine</i> , 2021, 13, 89.	3.6	10
9	Association of 17q22 Amplicon Via Cell-Free DNA With Platinum Chemotherapy Response in Metastatic Triple-Negative Breast Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 1777-1787.	1.5	5
10	Therapeutic Targeting of Minimal Residual Disease to Prevent Late Recurrence in Hormone-Receptor Positive Breast Cancer: Challenges and New Approaches. <i>Frontiers in Oncology</i> , 2021, 11, 667397.	1.3	11
11	Aggressive Subsets of Metastatic Triple Negative Breast Cancer. <i>Clinical Breast Cancer</i> , 2020, 20, e20-e26.	1.1	5
12	Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 2556-2564.	3.2	109
13	TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. <i>Journal of Clinical Oncology</i> , 2019, 37, 1081-1089.	0.8	251
14	Response to Olaparib in a Patient with Germline BRCA2 Mutation and Breast Cancer Leptomeningeal Carcinomatosis. <i>Npj Breast Cancer</i> , 2019, 5, 46.	2.3	26
15	Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 543-553.	0.8	162
16	Tumor fraction in cell-free DNA as a biomarker in prostate cancer. <i>JCI Insight</i> , 2018, 3, .	2.3	94
17	Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. <i>Nature Communications</i> , 2017, 8, 1324.	5.8	584
18	Multiplexed Elimination of Wild-Type DNA and High-Resolution Melting Prior to Targeted Resequencing of Liquid Biopsies. <i>Clinical Chemistry</i> , 2017, 63, 1605-1613.	1.5	23

#	ARTICLE	IF	CITATIONS
19	Individualized Molecular Analyses Guide Efforts (IMAGE): A Prospective Study of Molecular Profiling of Tissue and Blood in Metastatic Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 379-386.	3.2	50
20	Personalized Medicine in the Oncology Clinic: Implementation and Outcomes of the Johns Hopkins Molecular Tumor Board. <i>JCO Precision Oncology</i> , 2017, 2017, 1-19.	1.5	57
21	<i>ESR1</i> Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients. <i>Clinical Cancer Research</i> , 2016, 22, 993-999.	3.2	152
22	Tamoxifen for 5 years reduced 16-year risk for breast cancer in women at increased risk. <i>Annals of Internal Medicine</i> , 2015, 162, JC11.	2.0	0
23	Comparison of cell stabilizing blood collection tubes for circulating plasma tumor DNA. <i>Clinical Biochemistry</i> , 2015, 48, 993-998.	0.8	91
24	<i>HER2</i> missense mutations have distinct effects on oncogenic signaling and migration. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E6205-14.	3.3	69
25	<i>NDRG1</i> links p53 with proliferation-mediated centrosome homeostasis and genome stability. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 11583-11588.	3.3	21
26	Functional isogenic modeling of BRCA1 alleles reveals distinct carrier phenotypes. <i>Oncotarget</i> , 2015, 6, 25240-25251.	0.8	9
27	Analysis of BRCA2 loss of heterozygosity in tumor tissue using droplet digital polymerase chain reaction. <i>Human Pathology</i> , 2014, 45, 1546-1550.	1.1	12
28	DNA Binding Features of Human POT1. <i>Journal of Biological Chemistry</i> , 2004, 279, 13241-13248.	1.6	139